This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Matfin, G. Search for Related Content Social Bookmarking                         What's this?

Review: Biomarkers in clinical trials and drug development: measurement of cardiometabolic risk

Division of Endocrinology and Diabetes, Department of Medicine, New York University School of Medicine, New York, USA, gnnm{at}novonordisk.com

Cardiometabolic risk is linked to a cluster of modifiable factors, including established risk factors such as obesity, dyslipidaemia, raised blood pressure, and 'nontraditional' risk factors closely related to central (especially intra-abdominal) adiposity. These 'nontraditional' risk factors include dysfunction of inflammation, coagulation, platelets, fibrinolysis, lipoproteins, endothelium, plaque instability, and miscellaneous biological processes. Both the established ('traditional') and emerging ('nontraditional') cardiometabolic risk factors are components of the metabolic syndrome.

In patients with known or suspected cardiometabolic diseases, biomarkers are increasingly being explored as indicators of disease presence, severity or activity, prognosis and therapeutic efficacy. Many biomarkers have been proposed for prediction of the macrovascular (and microvascular) complications of cardiometabolic diseases. This review provides background information on biomarkers, and an assessment of the possible utility of biomarkers in clinical trials and drug development programmes that include measurement of cardiometabolic risk.

Key Words: biomarker • cardiometabolic risk • clinical end point • diabetes • metabolic syndrome • surrogate end point

The British Journal of Diabetes & Vascular Disease, Vol. 7, No. 3, 101-106 (2007)
DOI: 10.1177/14746514070070030201


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Matfin Aspects of drug development and clinical trials -- Part 2 The British Journal of Diabetes & Vascular Disease, July 1, 2007; 7(4): 149 - 150. [PDF]